Daewoong Pharma's Nabota (daxibotulinumtoxinA) has crossed 1 trillion won (~$750M USD) in annual sales, driven by strong domestic Korean demand and an accelerating global push. Nabota is a neuromodulator with a longer duration of action than Botox (up to 6 months vs. 3–4 months), positioning it as a differentiated alternative in markets where payers or patients value extended intervals between treatments.